造影剤市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、施術別、適応症別、地域別、競合別、2019年～2029年

造影剤の世界市場は、2023年に48億6,000万米ドルと評価され、2029年までCAGR 4.29％で成長すると予測されています。

世界の造影剤市場は、世界人口の高齢化と慢性疾患の罹患率の増加によって推進されています。これにより、高度な画像診断の需要が大幅に増加し、造影剤の必要性が高まっています。X線、CTスキャン、MRI、超音波などの医療用画像診断の技術進歩は、診断の正確性と効率を高め、造影剤の用途拡大に寄与しています。造影剤は従来のイメージング技術に使用されるだけでなく、インターベンショナル・ラジオロジー手技や画像誘導治療にも応用されています。造影剤の応用範囲の拡大は、世界の造影剤市場の成長にさらに貢献しています。

個別化医療へのパラダイムシフトは、オーダーメイドの治療アプローチのための正確な診断ツールを必要とします。個々の患者に特異的な分子標的や画像特性を提供できる造影剤製剤は、今後数年間の需要増加に貢献し、それによって世界の造影剤市場の成長に有利な機会を創出します。個々の患者の特性や病状に合わせて造影剤を調整することは、診断精度を高め、副作用を最小限に抑えます。これは、患者固有の遺伝的、環境的、ライフスタイル的要因に基づいて治療をカスタマイズする、精密医療に向けた幅広い動きと一致しています。

市場促進要因

画像診断手技の増加

慢性疾患の有病率の増加

画像診断モダリティの技術的進歩

非侵襲的処置に対する患者の嗜好

主な市場課題

代替画像技術との競合

安全性への懸念

主な市場動向

非イオン性造影剤へのシフト

Tranostic造影剤の出現

セグメント別洞察

施術別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の造影剤市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別（ヨード系造影剤、ガドリニウム系造影剤、マイクロバブル系造影剤、バリウム系造影剤）
  • 施術別（X線/コンピュータ断層撮影（CT）、磁気共鳴画像（MRI）、超音波）
  • 適応症別（循環器疾患、腫瘍、消化器疾患、神経疾患、その他の適応症）
  • 地域別
  • 企業別（2023年）
• 市場マップ

第6章 北米の造影剤市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • 手技別
  • 適応症別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の造影剤市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • 手技別
  • 適応症別
  • 国別
• 欧州国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋の造影剤市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • 手技別
  • 適応症別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の造影剤市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • 手技別
  • 適応症別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの造影剤市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • 手技別
  • 適応症別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品上市

第13章 世界の造影剤市場SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Bayer AG
• Bracco Diagnostic Inc.（Bracco Group）
• GE Healthcare Technologies Inc.
• Guerbet Group
• Lantheus Medical Imaging Inc
• Spago Nanomedical AB
• FUJIFILM Holdings Corporation
• Beijing Beilu Pharmaceutical Company Limited
• TAEJOON Pharmaceutical Co.,Ltd.

第16章 戦略的提言

第17章 免責事項

Global Contrast Media Market was valued at USD 4.86 Billion in 2023 and is anticipated to grow with a CAGR of 4.29% through 2029.The Global Contrast MediaMarket is driven by an aging global population and an increasing prevalence of chronic diseases. This in turn has significantly increased the demand for advanced diagnostic imaging procedures, fueling the need for contrast media. The technological advancements in medical imaging, such as X-ray, CT scans, MRI, and ultrasound, contribute to the expanding applications of contrast agents, enhancing the accuracy and efficiency of diagnoses. Contrast Media are not only used in traditional imaging techniques but also find applications in interventional radiology procedures and image-guided therapies. The expanding scope of applications of contrast media further contributes to the growth of global contrast media market.

The paradigm shift towards personalized medicine necessitates precise diagnostic tools for tailored treatment approaches. Contrast media formulations that can provide specific molecular targeting or imaging characteristics to individual patients would contribute to an increasing demand in the coming years, thereby creating lucrative opportunities for the growth of global contrast media market. Tailoring contrast agents to individual patient characteristics and medical conditions enhances diagnostic precision and minimizes adverse reactions. This aligns with the broader movement towards precision medicine, where treatments are customized based on patients unique genetic, environmental and lifestyle factors.

Key Market Drivers

Increasing Diagnostic Imaging Procedures

In the dynamic landscape of medical diagnostics, technological innovations play a pivotal role in shaping the trajectory of the contrast media market. As the industry witnesses a relentless pursuit of cutting-edge advancements, the seamless integration of these technologies into diagnostic imaging procedures has become a key driver for market growth.

In recent years, the surge in diagnostic imaging procedures, such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and angiography, has been a conspicuous trend. This surge can be attributed to the increasing need for accurate and timely diagnoses of various medical conditions. Notably, these imaging techniques rely heavily on the use of contrast media to enhance the visibility of internal structures, making them indispensable tools for healthcare professionals.

The escalating prevalence of chronic diseases, such as cardiovascular ailments and cancer, further amplifies the demand for diagnostic imaging procedures. Contrast media, with its ability to provide clearer and more detailed images, becomes instrumental in facilitating early detection and precise monitoring of these diseases. The aging global population, prone to age-related illnesses, contributes significantly to the sustained growth of the contrast media market.

Simultaneously, the realm of imaging technologies is undergoing rapid evolution, fueled by relentless innovation. High-resolution imaging and three-dimensional (3D) imaging technologies are becoming increasingly prevalent, driving the quest for more sophisticated and effective contrast agents. These advancements not only improve diagnostic accuracy but also open new avenues for personalized and targeted medical interventions.

The rise in healthcare expenditure globally is a catalyst for the adoption of advanced medical imaging technologies and contrast media. As healthcare systems prioritize investments in state-of-the-art diagnostic equipment, the demand for contrast media is propelled forward. Governments and private institutions alike are recognizing the pivotal role of contrast media in achieving diagnostic excellence, thereby allocating resources to enhance the accessibility and affordability of these technologies.

Stringent regulatory standards and compliance measures have become synonymous with the global contrast media market. Regulatory bodies play a crucial role in ensuring the safety and efficacy of contrast agents, thereby fostering trust among healthcare providers and patients. The adherence to these standards not only safeguards patient well-being but also contributes to the overall sustainability and credibility of the global contrast media market.

Increasing Chronic Disease Prevalence

The prevalence of chronic diseases represents a significant and escalating health challenge globally. Chronic diseases, characterized by prolonged and often slow-progressing conditions, encompass a diverse range of illnesses, including cardiovascular diseases, diabetes, cancer, and respiratory disorders. Several factors contribute to the increasing prevalence of these conditions, including aging populations, unhealthy lifestyle choices, and changes in dietary habits. As life expectancy rises, the likelihood of individuals developing chronic diseases also increases, placing a considerable burden on healthcare systems. The impact extends beyond individual health, affecting societal well-being and healthcare resources. The rising prevalence of chronic diseases require the need for early diagnosis and treatment. Chronic diseases such as neurological disorders, cardiovascular diseases, cancer, among others are effectively diagnosed using different kinds of imaging procedures. Contrast media plays a significant role in the accurate diagnosis and monitoring of these diseases, thereby fueling the global contrast media market growth.

Technological Advancements in Imaging Modalities

Technological advancements in medical imaging modalities represent a significant driver for the growth of the Global Contrast Media Market. Continuous innovations in X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound technologies have transformed diagnostic imaging, making it more precise and efficient. These advancements not only enable healthcare professionals to visualize internal structures with higher clarity but also expand the applications of contrast media.

For example, the development of high-resolution CT scanners and advanced MRI techniques allows for detailed imaging of soft tissues and vascular structures. Contrast media enhance the visibility of specific anatomical or pathological features during these procedures, providing crucial information for accurate diagnoses. Improved imaging technologies contribute to early detection, better characterization of diseases, and more targeted treatment strategies.

Companies in the contrast media market invest in research and development to align their products with the latest imaging technologies. The synergy between contrast agents and cutting-edge imaging modalities enhances diagnostic accuracy, driving the adoption of contrast-enhanced imaging across various medical specialties. As technological innovations continue, this driver remains integral to the market's growth, ensuring that contrast media play a pivotal role in the advancement of diagnostic capabilities in healthcare.

Patient Preferences for Non-Invasive Procedures

In recent years, a discernible shift in patient preferences has been observed within the realm of diagnostic imaging, with a notable inclination towards non-invasive procedures. This evolving trend has substantially influenced the dynamics of the contrast media market, as patients increasingly prioritize diagnostic methods that eschew invasive surgeries while maintaining high diagnostic accuracy. This transformation is rooted in the desire for a more patient-friendly and comfortable diagnostic experience.

As technology in the medical field advances, non-invasive diagnostic procedures have gained prominence, leveraging techniques such as CT scans, MRI scans, and angiography. These procedures, which often necessitate the use of contrast media, enable healthcare professionals to obtain detailed and precise images without resorting to intrusive interventions. The appeal of non-invasiveness lies not only in its ability to reduce patient discomfort but also in its potential to minimize recovery times and associated healthcare costs.

Furthermore, the preference for non-invasive procedures aligns with broader societal trends, where patients are becoming increasingly proactive in managing their health. The accessibility of information has empowered individuals to make informed choices about their medical care. Consequently, patients are more likely to opt for diagnostic methods that offer a balance between diagnostic efficacy and a minimally intrusive experience. The prominence of patient-centric care in the healthcare landscape has intensified the demand for imaging technologies that prioritize comfort and convenience.

The rise in patient preferences for non-invasive procedures has profound implications for companies operating in the contrast media market. Manufacturers of contrast agents must respond to this paradigm shift by developing products that not only enhance imaging capabilities but also prioritize safety, comfort, and ease of administration. Investing in research and development to create contrast agents with improved properties, such as reduced side effects and shorter administration times, becomes imperative to meet the evolving expectations of both healthcare professionals and patients.

Healthcare providers, too, need to adapt their service offerings to align with patient preferences. Investing in state-of-the-art imaging equipment and incorporating the latest contrast media technologies can enhance diagnostic capabilities while simultaneously catering to the growing demand for non-invasive procedures. Marketing strategies should be tailored to communicate the benefits of these advanced diagnostic methods, emphasizing the patient-friendly aspects that resonate with the evolving expectations of the healthcare consumer.

Key Market Challenges

Competition from Alternative Imaging Technologies

Alternative imaging techniques, such as PET scans and optical imaging modalities, pose competition to traditional contrast-enhanced imaging modalities like CT and MRI. The development of novel imaging techniques may disrupt the demand for contrast media. PET scans offer functional imaging capabilities that provide insights into metabolic activity and physiological processes. Compared to traditional anatomical imaging modalities like CT and MRI, PET scans can offer greater sensitivity and specificity in detecting certain diseases, such as cancer. The development of novel PET tracers continues to expand the clinical applications of PET imaging, potentially reducing the demand for contrast-enhanced CT or MRI scans in specific diagnostic scenarios. Similarly, optical imaging techniques, including fluorescence imaging and photoacoustic imaging, offer high resolution and real-time visualization of biological tissues. These modalities are particularly valuable in intraoperative imaging and preclinical research settings.

Safety Concerns

Adverse reactions to contrast media, such as allergic reactions, nephrotoxicity (especially with iodinated contrast media), and gadolinium retention (with certain MRI contrast agents), raise safety concerns among patients and healthcare providers.Allergic reactions are more common in patients with a history of allergies, asthma, or previous reactions to contrast agents. Managing allergic risks involves pre-screening patients, administering premedication when appropriate, and having emergency protocols in place to address acute reactions. Addressing these safety issues is essential to maintain trust in contrast media products. Iodinated contrast media, commonly used in CT scans, pose a risk of contrast-induced nephropathy (CIN), especially in patients with pre-existing kidney dysfunction. Strategies to mitigate nephrotoxicity include hydration protocols, selecting low-osmolality contrast agents, and avoiding unnecessary contrast administration in high-risk patients.

Key Market Trends

Shift towards Non-Ionic Contrast Agents

Ionic contrast agents contain positively or negatively charged particles, which can contribute to adverse reactions such as nephrotoxicity and allergic responses. Non-ionic contrast agents, on the other hand, have a reduced risk of adverse reactions due to their lower osmolality and reduced ion content. Non-ionic contrast agents are associated with a lower incidence of adverse reactions compared to ionic formulations. These reactions can range from mild symptoms such as nausea and rash to severe complications like anaphylaxis. Healthcare providers increasingly prefer non-ionic agents, particularly for high-risk patients and procedures, to minimize the risk of adverse events. Non-ionic contrast agents are often better tolerated by patients due to their reduced osmolality, which mitigates the discomfort associated with contrast administration. This improved patient comfort contributes to better overall patient experience during diagnostic procedures, leading to higher patient satisfaction rates.

Emergence of Theranostic Contrast Agents

Theranostic agents represent a convergence of diagnostic imaging and therapeutic capabilities within a single contrast agent. These agents enable not only the visualization of anatomical structures but also the monitoring of therapeutic responses and targeted drug delivery. Theranostic agents facilitate a personalized medicine approach by combining diagnostic imaging with therapeutic interventions. By incorporating both diagnostic and therapeutic functionalities into a single agent, theranostic contrast media enable clinicians to tailor treatment strategies based on individual patient characteristics and disease profiles.

Segmental Insights

Procedure Insights

By Procedure, X-ray/CT segment dominated in the Global Contrast Media Market in 2023 owing to numerous factors. X-ray and CT scans are widely used in diagnostic imaging techniques across medical settings. These imaging modalities play a crucial role in identifying and diagnosing a variety of medical conditions, ranging from bone fractures to internal organ abnormalities. Contrast media are substances injected into the body to enhance the visibility of specific tissues or organs during imaging procedures. In the case of X-ray and CT scans, contrast media help highlight blood vessels, organs, or other structures, providing greater clarity and detail in the resulting images. The increased diagnostic accuracy achieved using contrast agents in X-ray and CT scans has likely contributed to the segment's dominance. Furthermore, advancements in technology and imaging equipment have improved the overall performance and safety of contrast media used in X-ray and CT procedures.

Regional Insights

In 2023, the Contrast Media Market witnessed North America emerging as the unrivaled leader, solidifying its position through a confluence of factors that delineate its dominance.Several key elements contribute to the region's preeminence in this dynamic market landscape. Foremost among these factors is the robust infrastructure and technological prowess embedded within North America's healthcare system. The region boasts cutting-edge medical facilities and a comprehensive network of diagnostic imaging centers, which are pivotal in the administration of contrast media for various diagnostic procedures. The seamless integration of advanced imaging technologies, such as magnetic resonance imaging (MRI) and computed tomography (CT), across healthcare institutions in North America positions it at the forefront of diagnostic capabilities, consequently driving the demand for contrast media.

Additionally, the proactive approach of North America healthcare providers towards the adoption of novel medical technologies and contrast agents has significantly propelled market growth. The region exhibits a remarkable willingness to invest in research and development activities, resulting in the continual evolution of contrast media formulations with improved safety profiles and enhanced imaging capabilities. This commitment to innovation positions North America as a trendsetter, influencing global standards in the development and application of contrast media within diagnostic imaging.

Key Market Players

Bayer AG

Bracco Diagnostic Inc. (Bracco Group)

GE Healthcare Technologies Inc.

Guerbet Group

Lantheus Medical Imaging Inc

Spago Nanomedical AB

FUJIFILM Holdings Corporation

Beijing Beilu Pharmaceutical Company Limited

TAEJOON Pharmaceutical Co., Ltd.

Report Scope:

In this report, the Global Contrast Media Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Contrast Media Market,By Type:

Iodinated Contrast Media

Gadolinium-based Contrast Media

Microbubble Contrast Media

Barium-based Contrast Media

Contrast Media Market,By Procedure:

X-ray/Computed Tomography (CT)

Magnetic Resonance Imaging (MRI)

Ultrasound

Contrast Media Market,By Indication:

Cardiovascular Disease

Oncology

Gastrointestinal Disorders

Neurological Disorders

Other Indications

Contrast Media Market, By Region:

North America

• United States
• Canada
• Mexico

Europe

• Germany
• United Kingdom
• Italy
• France
• Spain

Asia Pacific

• China
• India
• Japan
• South Korea
• Australia

South America

• Brazil
• Argentina
• Colombia

Middle East Africa

• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Contrast Media Market.

Available Customizations:

Global Contrast Media Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validations
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.GlobalContrast Media MarketOutlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Type (Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media, and Barium-based Contrast Media)
  • 5.2.2.By Procedure (X-ray/Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and Ultrasound)
  • 5.2.3.By Indication (Cardiovascular Disease, Oncology, Gastrointestinal Disorders, Neurological Disorders, and Other Indications)
  • 5.2.4.By Region
  • 5.2.5.By Company (2023)
• 5.3.Market Map

6.North America Contrast Media Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Type
  • 6.2.2.By Procedure
  • 6.2.3.By Indication
  • 6.2.4.By Country
• 6.3.North America: Country Analysis
  • 6.3.1.United States Contrast Media Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Type
      • 6.3.1.2.2.By Procedure
      • 6.3.1.2.3.By Indication
  • 6.3.2.Canada Contrast Media Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Type
      • 6.3.2.2.2.By Procedure
      • 6.3.2.2.3.By Indication
  • 6.3.3.Mexico Contrast Media Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Type
      • 6.3.3.2.2.By Procedure
      • 6.3.3.2.3.By Indication

7.Europe Contrast Media Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Type
  • 7.2.2.By Procedure
  • 7.2.3.By Indication
  • 7.2.4.By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.Germany Contrast Media Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Type
      • 7.3.1.2.2.By Procedure
      • 7.3.1.2.3.By Indication
  • 7.3.2.United Kingdom Contrast Media Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Type
      • 7.3.2.2.2.By Procedure
      • 7.3.2.2.3.By Indication
  • 7.3.3.Italy Contrast Media Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecasty
      • 7.3.3.2.1.By Type
      • 7.3.3.2.2.By Procedure
      • 7.3.3.2.3.By Indication
  • 7.3.4.France Contrast Media Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Type
      • 7.3.4.2.2.By Procedure
      • 7.3.4.2.3.By Indication
  • 7.3.5.Spain Contrast Media Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Type
      • 7.3.5.2.2.By Procedure
      • 7.3.5.2.3.By Indication

8.Asia-Pacific Contrast Media Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Type
  • 8.2.2.By Procedure
  • 8.2.3.By Indication
  • 8.2.4.By Country
• 8.3.Asia-Pacific: Country Analysis
  • 8.3.1.China Contrast Media Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Type
      • 8.3.1.2.2.By Procedure
      • 8.3.1.2.3.By Indication
  • 8.3.2.India Contrast Media Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Type
      • 8.3.2.2.2.By Procedure
      • 8.3.2.2.3.By Indication
  • 8.3.3.Japan Contrast Media Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Type
      • 8.3.3.2.2.By Procedure
      • 8.3.3.2.3.By Indication
  • 8.3.4.South Korea Contrast Media Market Outlook
    • 8.3.4.1.Market Size Forecast
      • 8.3.4.1.1.By Value
    • 8.3.4.2.Market Share Forecast
      • 8.3.4.2.1.By Type
      • 8.3.4.2.2.By Procedure
      • 8.3.4.2.3.By Indication
  • 8.3.5.Australia Contrast Media Market Outlook
    • 8.3.5.1.Market Size Forecast
      • 8.3.5.1.1.By Value
    • 8.3.5.2.Market Share Forecast
      • 8.3.5.2.1.By Type
      • 8.3.5.2.2.By Procedure
      • 8.3.5.2.3.By Indication

9.South America Contrast Media Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Type
  • 9.2.2.By Procedure
  • 9.2.3.By Indication
  • 9.2.4.By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil Contrast Media Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Type
      • 9.3.1.2.2.By Procedure
      • 9.3.1.2.3.By Indication
  • 9.3.2.Argentina Contrast Media Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Type
      • 9.3.2.2.2.By Procedure
      • 9.3.2.2.3.By Indication
  • 9.3.3.Colombia Contrast Media Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Type
      • 9.3.3.2.2.By Procedure
      • 9.3.3.2.3.By Indication

10.Middle East and Africa Contrast Media Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Type
  • 10.2.2.By Procedure
  • 10.2.3.By Indication
  • 10.2.4.By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa Contrast Media Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Type
      • 10.3.1.2.2.By Procedure
      • 10.3.1.2.3.By Indication
  • 10.3.2.Saudi Arabia Contrast Media Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Type
      • 10.3.2.2.2.By Procedure
      • 10.3.2.2.3.By Indication
  • 10.3.3.UAE Contrast Media Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Type
      • 10.3.3.2.2.By Procedure
      • 10.3.3.2.3.By Indication

11.Market Dynamics

• 11.1.Drivers
• 11.2.Challenges

12.Market Trends Developments

• 12.1.Recent Development
• 12.2.Mergers Acquisitions
• 12.3. Product Launches

13.Global Contrast Media Market: SWOT Analysis

14.Porter's Five Forces Analysis

• 14.1.Competition in the Industry
• 14.2.Potential of New Entrants
• 14.3.Power of Suppliers
• 14.4.Power of Customers
• 14.5.Threat of Substitute Products

15.Competitive Landscape

• 15.1.Bayer AG
  • 15.1.1.Business Overview
  • 15.1.2.Product Service Offerings
  • 15.1.3.Recent Developments
  • 15.1.4.Key Personnel
  • 15.1.5.SWOT Analysis
• 15.2.Bracco Diagnostic Inc. (Bracco Group)
• 15.3.GE Healthcare Technologies Inc.
• 15.4.Guerbet Group
• 15.5.Lantheus Medical Imaging Inc
• 15.6.Spago Nanomedical AB
• 15.7.FUJIFILM Holdings Corporation
• 15.8.Beijing Beilu Pharmaceutical Company Limited
• 15.9.TAEJOON Pharmaceutical Co.,Ltd.

16.Strategic Recommendations

17.About Us Disclaimer